microLIQUID is now a TE Connectivity Company.




Molecular diagnostics have improved the diagnosis and treatmentof millions of patients worldwide allowing clinicians to have an early diagnose patients earlier as well as providing better ongoing therapies. At microLIQUID has the capacity towedevelop fully automated molecular diagnostic systems based on microfluidics.

Non microfluidic diagnostic instruments usually require morean importantquantityof costly reagents, long analysis time, established lab infrastructure, and trained professionals to operate, which limits their availability for large-scale screening applications in developed countries and primary care in developing countries. There is a strong demand for robust, cost-effective, and simple-to-operate instruments for molecular diagnostics.

Microfluidicssystems have many advantages, such as short analysis time, reduction in fabrication costs, and low sample/reagent consumption.Besides, Mmost current microfluidicdiagnostic devices are designed to target a single disease, such as a given cancer or a variety of pathogens. The future of molecular diagnostics lies in highly multiplexed microfluidic devices that can screen for potentially hundreds of diseases simultaneously.microLIQUIDis concerned with the development ofdiagnostic systems, having the experience and expertise to develop and manufacture fully automated molecular diagnostics systems

For more information: www.microLIQUID.com

1.Microfluidics for molecular diagnostics

2.Molecular diagnostics development

3.Molecular diagnostic device manufacturing

4.Molecular assay development

5.Molecular assay manufacturing